Report Name: AMAG Pharmaceuticals Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
AMAG Pharmaceuticals Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
AMAG Pharmaceuticals – Business Description:
AMAG Pharmaceuticals is a pharmaceutical company which focuses on maternal health, anemia and cancer supportive care. The company has operations in the US and the UK. The company manufactures and markets three products: Feraheme (ferumoxytol, injection for intravenous (IV)), Makena (hydroxyprogesterone caproate injection) and MuGard (mucoadhesive oral wound rinse). AMAG’s Feraheme is used for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is developed for use as an intravenous, or IV, iron replacement therapeutic agent for the treatment of iron deficiency anemia (IDA). In FY2016, the Feraheme segment reported revenues of USD97.1 million, which accounted for 18.2% of the company’s total revenue. The company’s MuGard is a mucoadhesive oral wound rinse for the management of oral mucositis, stomatiits and all types of oral wounds. In FY2016, the Mugard segment reported revenues of USD1.1 million, which accounted for 0.2% of the company’s total revenue. AMAG’s Makena is a progestin indicated to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth. The company also offers Cord Blood Registry (CBR) services related in the collection, processing and storage of umbilical cord blood and cord tissue units. In FY2016, the Makena segment reported revenues of USD334.1 million, which accounted for 62.8% of the company’s total revenue. In FY2016, the Services segment reported revenues of USD99.6 million, which accounted for 18.7% of the company’s total revenue. In FY2016, the Other segment reported revenues of USD0.3 million, which accounted for 0.1% of the company’s total revenue. The company’s subsidiaries include AMAG Securities Corporation, AMAG Europe Limited, AMAG Pharmaceuticals Canada Corporation, AMAG Europe Limited, FP1096, Inc., Lumara Health IP Ltd., Lumara Health IP Ltd., Lumara Health IP Ltd. and CBR Acquisition Holdings Corp.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757